JPWO2021071965A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2021071965A5 JPWO2021071965A5 JP2022521134A JP2022521134A JPWO2021071965A5 JP WO2021071965 A5 JPWO2021071965 A5 JP WO2021071965A5 JP 2022521134 A JP2022521134 A JP 2022521134A JP 2022521134 A JP2022521134 A JP 2022521134A JP WO2021071965 A5 JPWO2021071965 A5 JP WO2021071965A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- reductase inhibitor
- aldose reductase
- composition according
- halogen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025063234A JP2025100631A (ja) | 2019-10-08 | 2025-04-07 | ホスホマンノムターゼ２欠損の処置のためのアルドースレダクターゼ阻害剤 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962912441P | 2019-10-08 | 2019-10-08 | |
| US62/912,441 | 2019-10-08 | ||
| PCT/US2020/054607 WO2021071965A1 (en) | 2019-10-08 | 2020-10-07 | Aldose reductase inhibitors for treatment of phosphomannomutase 2 deficiency |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025063234A Division JP2025100631A (ja) | 2019-10-08 | 2025-04-07 | ホスホマンノムターゼ２欠損の処置のためのアルドースレダクターゼ阻害剤 |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2022552831A JP2022552831A (ja) | 2022-12-20 |
| JP2022552831A5 JP2022552831A5 (https=) | 2023-10-11 |
| JPWO2021071965A5 true JPWO2021071965A5 (https=) | 2023-10-11 |
| JP7778686B2 JP7778686B2 (ja) | 2025-12-02 |
Family
ID=75437528
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022521134A Active JP7778686B2 (ja) | 2019-10-08 | 2020-10-07 | ホスホマンノムターゼ２欠損の処置のためのアルドースレダクターゼ阻害剤 |
| JP2025063234A Pending JP2025100631A (ja) | 2019-10-08 | 2025-04-07 | ホスホマンノムターゼ２欠損の処置のためのアルドースレダクターゼ阻害剤 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025063234A Pending JP2025100631A (ja) | 2019-10-08 | 2025-04-07 | ホスホマンノムターゼ２欠損の処置のためのアルドースレダクターゼ阻害剤 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20220226323A1 (https=) |
| EP (1) | EP4041219A4 (https=) |
| JP (2) | JP7778686B2 (https=) |
| CN (3) | CN114667139B (https=) |
| AU (1) | AU2020363699A1 (https=) |
| BR (1) | BR112022005895A2 (https=) |
| CA (1) | CA3153108A1 (https=) |
| IL (1) | IL291946A (https=) |
| MX (1) | MX2022004270A (https=) |
| WO (1) | WO2021071965A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL272246B2 (en) | 2017-07-28 | 2026-01-01 | Applied Therapeutics Inc | History of 2-(4-oxo/thioketone/azo-3-((substituted)benzo[d]thiazol-2-yl)methyl)- 3,4-dihydrothieno[3,4-d]pyridazin-1-yl)acetic acid for use as an aldose reductase inhibitor for the treatment of galactosemia or prevention of galactosemia-related complications |
| CN113840825A (zh) | 2019-04-01 | 2021-12-24 | 应用治疗公司 | 醛糖还原酶抑制剂 |
| WO2020227430A1 (en) | 2019-05-07 | 2020-11-12 | University Of Miami | Treatment and detection of inherited neuropathies and associated disorders |
| WO2024064147A1 (en) * | 2022-09-20 | 2024-03-28 | Mayo Foundation For Medical Education And Research | Treating congenital disorders of glycosylation |
| WO2025171282A1 (en) * | 2024-02-09 | 2025-08-14 | Landry's Smile, Llc | Methods for treating congenital disorders of glycosylation |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007008548A2 (en) * | 2005-07-07 | 2007-01-18 | Sirtris Pharmaceuticals, Inc. | Methods and related compositions for treating or preventing obesity, insulin resistance disorders, and mitochondrial-associated disorders |
| US20110257233A1 (en) * | 2010-03-19 | 2011-10-20 | Sanford-Burnham Medical Research Institute | Benzoisothiazolones as inhibitors of phosphomannose isomerase |
| US8916563B2 (en) | 2010-07-16 | 2014-12-23 | The Trustees Of Columbia University In The City Of New York | Aldose reductase inhibitors and uses thereof |
| WO2013123403A1 (en) * | 2012-02-15 | 2013-08-22 | Sanford-Burnham Medical Research Institute | Theranostics platform and methods of use |
| DK3352754T3 (da) | 2016-06-21 | 2020-12-07 | Univ Columbia | Aldosereduktaseinhibitorer og fremgangsmåder til anvendelse deraf |
| EP3275863A1 (en) * | 2016-07-29 | 2018-01-31 | Universidad Autónoma de Madrid | Compounds for treating congenital disorders of glycosylation |
| IL272246B2 (en) * | 2017-07-28 | 2026-01-01 | Applied Therapeutics Inc | History of 2-(4-oxo/thioketone/azo-3-((substituted)benzo[d]thiazol-2-yl)methyl)- 3,4-dihydrothieno[3,4-d]pyridazin-1-yl)acetic acid for use as an aldose reductase inhibitor for the treatment of galactosemia or prevention of galactosemia-related complications |
| CA3110162A1 (en) * | 2018-08-20 | 2020-02-27 | Maggie's Pearl, Llc | Methods for treating congenital disorders of glycosylation |
| CN113840825A (zh) * | 2019-04-01 | 2021-12-24 | 应用治疗公司 | 醛糖还原酶抑制剂 |
-
2020
- 2020-10-07 CA CA3153108A patent/CA3153108A1/en active Pending
- 2020-10-07 CN CN202080070704.XA patent/CN114667139B/zh active Active
- 2020-10-07 JP JP2022521134A patent/JP7778686B2/ja active Active
- 2020-10-07 IL IL291946A patent/IL291946A/en unknown
- 2020-10-07 EP EP20875044.8A patent/EP4041219A4/en active Pending
- 2020-10-07 AU AU2020363699A patent/AU2020363699A1/en active Pending
- 2020-10-07 BR BR112022005895A patent/BR112022005895A2/pt unknown
- 2020-10-07 CN CN202510299373.1A patent/CN120114457A/zh active Pending
- 2020-10-07 MX MX2022004270A patent/MX2022004270A/es unknown
- 2020-10-07 CN CN202510299188.2A patent/CN120093757A/zh active Pending
- 2020-10-07 WO PCT/US2020/054607 patent/WO2021071965A1/en not_active Ceased
-
2022
- 2022-04-07 US US17/715,401 patent/US20220226323A1/en active Pending
-
2025
- 2025-04-07 JP JP2025063234A patent/JP2025100631A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Li et al. | IFN-lambda preferably inhibits PEDV infection of porcine intestinal epithelial cells compared with IFN-alpha | |
| US9676808B2 (en) | 2′,4′-substituted nucleosides as antiviral agents | |
| KR101594166B1 (ko) | C형 간염 바이러스의 억제제 | |
| JP2013014624A (ja) | 感染症の処置のためのｉｌ−２３アンタゴニストの使用 | |
| JP2008503515A5 (https=) | ||
| JP2019524795A (ja) | 置換ヌクレオシド、ヌクレオチド、及びそのアナログ | |
| KR20140014375A (ko) | 인터페론-알파 반응과 연관된 유전자 마커 | |
| JP2012517444A5 (https=) | ||
| Meerbach et al. | Inhibitory effects of novel nucleoside and nucleotide analogues on Epstein—Barr virus replication | |
| JP2016518453A (ja) | ４’−フルオロ−２’−メチル置換ヌクレオシド誘導体 | |
| JP2014532716A5 (https=) | ||
| Stankiewicz-Drogon et al. | Synthesis of new acridone derivatives, inhibitors of NS3 helicase, which efficiently and specifically inhibit subgenomic HCV replication | |
| CA2699280A1 (en) | Method of treating hepatitis c patients | |
| JP2006513205A5 (https=) | ||
| JPWO2021071965A5 (https=) | ||
| JP2008543847A5 (https=) | ||
| JP2026040489A (ja) | 骨髄増殖性新生物の治療のためのリシン特異的ヒストンデメチラーゼ阻害剤 | |
| Kumar et al. | High mobility group box (HMGB) proteins of Plasmodium falciparum: DNA binding proteins with pro-inflammatory activity | |
| Akemi et al. | Cloning and expression of a cDNA encoding mouse indoleamine 2, 3-dioxygenase | |
| CN1431907A (zh) | 治疗丁型肝炎病毒感染的方法 | |
| JP2005526051A5 (https=) | ||
| Fernandes et al. | Shewanella algae, an emerging human pathogen: A series of four cases from a Portuguese hospital | |
| Broser et al. | Elevated interleukin-8 in the alveolitis of individuals with asbestos exposure | |
| JP2021505634A5 (https=) | ||
| Singla et al. | Levels of hepatitis B virus replicative intermediate in serum samples of chronic hepatitis B patients |